Headquartered in Emeryville, CA Fiscal year ends December NASDAQ: KYTX kyvernatx.com
Kyverna Therapeutics (Nasdaq: KYTX) is a late-stage clinical immunology company developing transformative therapies for neurologic autoimmune diseases. The company's lead candidate, miv-cel (mivocabtagene autoleucel, KYV-101), is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation designed for potency and tolerability. Miv-cel is under investigation for B-cell-driven autoimmune diseases including stiff person syndrome (SPS), generalized myasthenia gravis (gMG), and progressive multiple sclerosis (PMS). With a single administration, miv-cel has the potential to achieve deep B-cell depletion and immune system reset. The company is advancing a rolling BLA submission for SPS, conducting a Phase 3 registrational trial in gMG, and exploring development in PMS. Kyverna holds three RMAT designations from the FDA across its neuroimmunology franchise. The company is pre-revenue and is transitioning toward commercial-stage operations with plans for a potential commercial launch in SPS in 2027. Updated
A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity or…
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry significant risk, but their…
Kyverna Therapeutics (Nasdaq: KYTX) is a late-stage clinical immunology company developing transformative therapies for neurologic autoimmune diseases.
The Wall Street consensus 12-month price target for KYTX is $30.40.
